Compliance of Scored Tablet Halves Produced by Palestinian Pharmaceutical Companies with the New European Pharmacopoeia Requirements

다국어 초록 (Multilingual Abstract)

The aim of this study was to evaluate the weight uniformity of commonly divided tablets produced by Palestinian Pharmaceutical Companies and to evaluate the importance of both patient- and formulation-related variables on the splitting results. Eighty-four volunteers were enrolled in this study; their age, gender and occupation were documented in order, and the effect of these variables on the tablet splitting results was evaluated. Each volunteer was asked to divide six scored tablets of each product tested and was given clear instructions on how to conduct the splitting process. The split units were individually weighed and the RSD for each product was calculated as instructed in the European Pharmacopoeia (Ph. Eur. 5.5). Only one scored tablet product passed the Ph. Eur. test of mass uniformity, while the remaining 13 products failed; this indicates that the splitting of these tablet products is not a reliable means for the provision of accurate doses to patients. Age, gender and occupation of volunteers were not found to be predictive of any variability noted in the splitting results. The only factors that were suspected to be linked to passing the splitting test, as per the European Pharmacopoeia, were the shape, friability and hardness of the tablets. As a result of this study, we believe that the practice of dividing tablets, which should provide therapeutic and economic benefits for the patient, may potentially cause significant problems, especially in drugs with low therapeutic indices. Tablets produced by Palestinian Pharmaceutical Companies should comply with the new Ph. Eur. splitting regulations to reduce this potential for complications.

참고문헌 (Reference)

1 Rosenberg, J. M., "Weight variability of pharmacist-dispensed split tablets" 42 : 200-205, 2002

2 Carr-Lopez, S. M., "The tablet splitter: barrier to compliance or cost-saving instrument" 52 : 2707-2708, 1995

3 "Tablets, European Pharmacopoeia Suppl. 4.1, Council of Europe; European Directorate for the Quality of Medicine, Strasbourg, Monograph 0478 (2002)"

4 APhA Strategic Directions Committee, "Tablet splitting: evaluating appropriateness for patients" 44 : 324-325, 2004

5 Marriott, J. L., "Splitting tablets" 25 : 133-135, 2002

6 Fawell, N. G., "Relationship between tablet splitting and compliance, drug acquisition cost, and patient acceptance" 56 : 2542-2545, 1999

7 Rodenhuis, N., "Patient experiences with the performance of tablet score lines needed for dosing" 25 : 173-176, 2003

8 Biron, C., "Oral anticoagulant drugs: do not cut tablets in quarters" 82 : 1201-, 1999

9 Anonymous, "Note for Guidance on Development Pharmaceutics"

10 Schumann, C., "Neue Tablettenform: Exakt Teilbar New tablet form: accurate divisible" 140 : 39-45, 1995

11 Kristensen, H. G., "Mass uniformity of tablets broken by hand" 7 : 298-302, 1995

12 Duncan, M. C., "Effect of tablet splitting on serum cholesterol concentrations" 36 : 205-209, 2002

13 Lüdemann, J., "Dosierungsgenauigkeit teilbarer tabletten. Realisierung uber die tablettenform" 134 : 27-30, 1994

14 Gupta, P., "Broken tablets: does the sum of the parts equal the whole" 45 : 1498-, 1988

15 van Santen, E., "Breaking of scored tablets: a review" 53 : 139-145, 2002

16 Spang, R., "Breakability of tablets and film-coated dragees" 57 : 99-111, 1982

17 McDevitt, J. T., "Accuracy of tablet splitting" 18 : 193-197, 1998